High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects

Annals of Oncology

Volumn 8, Issue 10, 1997, Pages 1041-1044

  Eriksson, B ^a,c   Renstrup, J ^b   Imam, H ^a   Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b IPSEN   (France)

^c University Hospital   (Sweden)

Author keywords

Apoptosis; Chromogranin; Gastrointestinal tumors; Lanreotide; Neuroendocrine; Positron emission tomography; U 5 HIAA

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EYE TOXICITY; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; MALE; MUSCLE CRAMP; NEUROENDOCRINE TUMOR; NEUROTOXICITY; PANCREAS TUMOR; PRIORITY JOURNAL; SCINTISCANNING; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; PILOT PROJECTS; SOMATOSTATIN;

EID: 0030667438     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008205415035     Document Type: Article

References (12)

1. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical percutaneous needle biopsy samples of carcinoids and ilets cell carcinomas. Cancer Res 1990; 50: 5969-77.
2. 1]-Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for somatostatin analogue treatment. Eur J of Endocrinol 1994; 131: 577-81.
3. Lamberts SW, van der Lely AJ, de Herder WW. Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
4. Yamada Y, Post SR, Wang K et al. Cloning and characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci 1992; 89: 251-5.
5. Yamada Y, Racine T, Law SF et al. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992; 6: 2136-42.
6. Yamada Y, Kagimoto S, Kubota A et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Comm 1993; 195: 844-52.
7. O'Carrol AM, Lolait SJ, Könich M, Mahan LC. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 1992; 42: 939-46.
8. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
9. Imam H, Eriksson B, Lukinius A et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with soraatostatin analogs. Acta Oncol (in press).
10. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-96.
11. Szende B, Lapis K, Redding TW et al. Growth inhibition of MTX mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat 1989; 14: 307-14.
12. Ruszniewski P. Ducreux M, Chayvialle JA et al. Treatment of the carcinoid syndrome with long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996; 39: 279-83.